EGFR and non-small cell lung carcinoma: This study indicated that although a statistically significant difference was not discovered in PFS among the three groups of advanced NSCLC patients who chose ICIs + chemotherapy, ICIs + chemotherapy + antiangiogenic therapy, and chemotherapy + antiangiogenic therapy after EGFR-TKIs resistance, patients receiving triple therapy are more likely to have better survival benefits.